We propose to organize a cooperative group of institutions and individuals that will comprise the American College of Radiology Oncologic Imaging Network (ACROIN). ACROIN will develop clinical trials through its committee structure and the recruitment of ad hoc participants to rigorously assess both emerging and more stable imaging technologies as they relate to patients with cancer. Ultimately, ACROIN's goals are to: increase patient survival; improve quality of life through reduced invasiveness of diagnosis and treatment; improve patients' sense of well-being through greater rapidity and certainty of diagnosis and treatment; reduce diagnostic and therapeutic morbidity; hasten the translation of discovery to clinical technology; and speed the diffusion of worthwhile technologies into clinical practice. ACROIN will accomplish these goals by several strategies, including: a focus on the most important malignancies and technologies; an appropriate mix of trials between emerging and mature technologies; evaluation using a variety of endpoints -from tests of simple accuracy to assessment of patient outcomes and cost-effectiveness, according to the maturity of the technology; flexible, broad-based collaboration between core and ad hoc participants, including institutions, scientists, industry, payors, and patients; establishment of an organization designed to speed the development and implementation of trials and hasten dissemination of their findings; and reliance on the extensive past experience of the Headquarters and Biostatistical Center in conducting high quality clinical trials. ACROIN has developed an extensive committee structure to fulfill its functions; secured the commitment of 42 leading departments of radiology that they will try to qualify as core institutional participants; received letters of collaboration from eight other cooperative groups - each of which has designated a representative to ACROIN; and received the promises of a number of commercial companies and insurers that they will participate in and support ACROIN once it is established.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA080098-01
Application #
2743624
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (O1))
Program Officer
Menkens, Anne E
Project Start
1999-03-06
Project End
2003-12-31
Budget Start
1999-03-06
Budget End
1999-12-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
City
Reston
State
VA
Country
United States
Zip Code
20191
Kaufman, Annette R; Dwyer, Laura A; Land, Stephanie R et al. (2018) Smoking-related health beliefs and smoking behavior in the National Lung Screening Trial. Addict Behav 84:27-32
Cochran, Jeffrey M; Busch, David R; Leproux, Anaïs et al. (2018) Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. J Biomed Opt 24:1-11
Newitt, David C; Malyarenko, Dariya; Chenevert, Thomas L et al. (2018) Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham) 5:011003
Ng, Chaan S; Zhang, Zheng; Lee, Susanna I et al. (2017) CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res 23:3684-3691
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Hofheinz, Frank; Apostolova, Ivayla; Oehme, Liane et al. (2017) Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials. J Nucl Med 58:1770-1775
Aide, Nicolas; Lasnon, Charline; Veit-Haibach, Patrick et al. (2017) EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 44:17-31
Gu, Fangyi; Cheung, Li C; Freedman, Neal D et al. (2017) Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening. J Thorac Oncol 12:1646-1653
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Wong, Jason Y Y; Bassig, Bryan A; Seow, Wei Jie et al. (2017) Lung cancer risk in welders and foundry workers with a history of heavy smoking in the USA: The National Lung Screening Trial. Occup Environ Med 74:440-448

Showing the most recent 10 out of 121 publications